# US 2021/0277404 A1 · Methods for making a synthetic gene

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277404 A1
- Document ID: US20210277404A1
- Status: Published application
- Kind: A1
- Application number: 17/320,513
- Filed: 2021-05-14
- Published: 2021-09-09
- Earliest claimed: 2014-12-22
- Assignees: AgBiome, Inc.
- Applicants: Agbiome, Inc.
- Inventors: JAMES R. HENRIKSEN
- Web page: https://patentgrep.com/patent/US20210277404A1

## CPC

- C12N 15/67: General methods for enhancing the expression
- C07K 14/325: Bacillus thuringiensis crystal peptides, i.e. delta-endotoxins
- C12N 15/8216: {Methods for controlling, regulating or enhancing expression of transgenes in plant cells}
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B 30/20: Sequence assembly
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

Methods for making a synthetic gene are provided. The methods find use in optimizing a candidate gene nucleic acid sequence for expression in a selected target expression system. The method identifies stable or retained sequences in the candidate gene nucleic acid sequence, identifies disallowed sequences, develops a statistical model based on a whole genome, a partial genome, or transcriptome sequences of the target expression system, generates an optimized candidate gene nucleic acid sequence for use in the target expression system, and makes a synthetic gene comprising the optimized candidate gene nucleic acid sequence. The method allows for optimization of the candidate gene nucleic acid sequence without removing certain stable or retained sequences. Rather, the activity of these sites is positionally modulated or inactivated through upstream and downstream modifications of codons and/or sequence patterns.

## Claims

### Claim 1

1) A method for making a synthetic gene, said method comprising:
(a) identifying one or more stable or retained sequences in a candidate gene nucleic acid sequence;
(b) identifying one or more disallowed sequences;
(c) using a statistical model based on a whole genome, a partial genome, or transcriptome sequences of a target expression system, wherein the statistical model comprises frequency of codon preference in the target expression system and frequency of nucleic acid sequences that are 5′ and 3′ to sequences that correspond to the one or more stable or retained sequences in the candidate gene nucleic acid sequence;
(d) generating an optimized candidate gene nucleic acid sequence for use in the target expression system, wherein generating comprises:
(i) modifying localized sequences in the candidate gene nucleic acid sequence that are 5′ and/or 3′ to the one or more stable or retained sequences, wherein the modifications are based on the statistical model and often do not include a preferred codon modification, and wherein the modifications optimize gene expression in the target expression system;
(ii) optionally, modifying additional loci throughout the candidate gene nucleic acid sequence based on the statistical model, wherein the modifications do not include the modification of one or more stable or retained sequences or previously modified sequences, and wherein the modifications optimize gene expression in the target expression system; and
(iii) optionally, modifying the one or more disallowed sequences in the candidate gene nucleic acid sequence; and
(e) making a synthetic gene comprising the optimized candidate gene nucleic acid sequence.

### Claim 2 (depends on 1)

2) The method of claim 1, wherein the synthetic gene is incorporated into an expression cassette.

### Claim 3 (depends on 2)

3) The method of claim 2, wherein the expression cassette is introduced into a host cell, and wherein the host cell expresses the synthetic gene.

### Claim 4

4) The method of any preceding claim, wherein the target expression system comprises a target organism or a target in vitro expression system.

### Claim 5

5) The method of any preceding claim, wherein the one or more stable or retained sequences comprise polyadenylation sites, termination sites, RNA destabilizing sites, ATTTA motifs, exon-intron splice site signals, transposon-like repeats, restriction enzyme recognition sites, sequences deleterious to gene expression, or any combination thereof.

### Claim 6

6) The method of any preceding claim, wherein the one or more disallowed sequences comprise polyadenylation sites, termination sites, RNA destabilizing sites, ATTTA motifs, exon-intron splice site signals, transposon-like repeats, restriction enzyme recognition sites, sequences deleterious to gene expression, or any combination thereof.

### Claim 7

7) The method of any preceding claim, wherein the one or more disallowed sequences are scored.

### Claim 8

8) The method of any preceding claim, wherein selected subsets of the whole genome, the partial genome, or the transcriptome sequences are used for developing the statistical model.

### Claim 9

9) The method of any preceding claim, wherein selected subsets of the whole genome, the partial genome, or the transcriptome sequences are weighted in the statistical model.

### Claim 10

10) The method of any preceding claim, wherein the statistical model further comprises compositional patterns in the whole genome, the partial genome, or the transcriptome sequences of the target expression system.

### Claim 11 (depends on 10)

11) The method of claim 10, wherein the compositional patterns are normalized.

### Claim 12 (depends on 10, 11)

12) The method of claim 10 or claim 11, wherein the compositional patterns comprise the GC-type content, or any combination thereof.

### Claim 13

13) The method of any preceding claim, wherein the localized modifications of the candidate gene nucleic acid sequence comprise substitutions of one or more codons that are 5′ to the one or more stable or retained sequences, 3′ to the one or more stable or retained sequences, or a combination thereof.

### Claim 14

14) The method of any preceding claim, wherein the localized modifications of the candidate gene nucleic acid sequence comprise substitutions of one or more sequence patterns that are 5′ to the one or more stable or retained sequences, 3′ to the one or more stable or retained sequences, or a combination thereof.

### Claim 15

15) The method of any preceding claim, wherein the modifications of additional loci throughout the candidate gene nucleic acid sequence comprise modifications to all regularly spaced or defined loci, wherein the modifications do not include the one or more stable or retained sequences or previously modified sequences.

### Claim 16

16) The method of any preceding claim, wherein the modifications of additional loci throughout the candidate gene nucleic acid sequence comprise localized modifications of the one or more disallowed sequences.

### Claim 17

17) The method of any preceding claim, wherein the modifications of additional loci throughout the candidate gene nucleic acid sequence comprise one or more substitutions of codons that are present at corresponding positions in the target expression system.

### Claim 18

18) The method of any preceding claim, wherein preferences for the modifications of localized sequences in the candidate gene nucleic acid sequence, and preferences for the modifications of additional loci throughout the candidate gene nucleic acid sequence, are based on:
(a) resemblance to sequences observed in corresponding positions in the target expression system or related loci in other genes;
(b) removal of the one or more disallowed sequences;
(c) preventing the introduction of the one or more disallowed sequences;
(d) preservation of the one or more stable or retained sequences;
(e) codon preference; or
(f) any combination of (a) to (e).

### Claim 19

19) The method of any preceding claim, wherein preferences for modifications of the candidate gene nucleic acid sequence are scored simultaneously with weighted scores or are scored in separate sub-steps.

### Claim 20

20) The method of any preceding claim, wherein the frequency of codon preference in the target expression system determined by the statistical model is normalized.

### Claim 21

21) The method of any preceding claim, wherein the candidate gene nucleic acid sequence and the optimized candidate gene nucleic acid sequence encode the same polypeptide.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

22) The method of any one of claims 1-20, wherein the optimized candidate gene nucleic acid sequence encodes a modified polypeptide.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

23) The method of any one of claims 1-20, wherein the optimized candidate gene nucleic acid sequence comprises one or more stable or retained sequences at a different position relative to their endogenous position(s) in the candidate gene nucleic acid sequence.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

24) The method of any one of claims 1-20, wherein the optimized candidate gene nucleic acid sequence further comprises one or more substitutions that are not based on the statistical model.
